Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2017-01-04 Earnings Release
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
ALK opjusterer de finansielle forventninger til 2016 som følge af et bedre end forventet salg i fjerde kvartal
Earnings Release Classification · 95% confidence The document is a short company release (2030 characters) announcing an upward revision of the company's 2016 financial guidance. It provides key highlights of the expected revenue and EBITDA growth but is not the full financial report itself. As it is an initial announcement of financial results/guidance, it fits the definition of an Earnings Release (ER). FY 2016
2017-01-04 English
ALK opjusterer de finansielle forventninger til 2016 som følge af et bedre end forventet salg i fjerde kvartal
Earnings Release Classification · 95% confidence The document is a short corporate announcement (Selskabsmeddelelse) from ALK regarding an upward adjustment of their financial expectations for the 2016 fiscal year. It provides key highlights of the revised guidance (revenue and EBITDA) but is not the full financial report itself. Since it is an initial announcement of financial results/guidance and not a full report, it falls under the Earnings Release category. FY 2016
2017-01-04 English
Regulatory Filings 2016
Regulatory Filings
2016-12-22 Danish
Regulatory Filings 2016
Regulatory Filings
2016-12-22 English
ALK styrker tilstedeværelse i USA gennem virksomhedsopkøb
M&A Activity Classification · 100% confidence The document is a corporate announcement (Selskabsmeddelelse) regarding the acquisition of Allergy Laboratories, Inc. and Crystal Laboratory LLC by ALK-Abelló A/S. It details the purchase price, strategic rationale, and impact on the company's supply chain and financial outlook. Since this is a specific announcement regarding a merger/acquisition transaction, it falls under the M&A Activity category.
2016-12-22 English
ALK styrker tilstedeværelse i USA gennem virksomhedsopkøb
M&A Activity Classification · 100% confidence The document is a company press release announcing the acquisition of Allergy Laboratories, Inc. and Crystal Laboratory LLC by ALK. It details the transaction value, strategic rationale, and expected financial impact. This falls under M&A activity (mergers and acquisitions).
2016-12-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.